Capacity constraints in biomanufacturing, although far less impactful than what was occurring 10 years ago, continue to affect the industry in different ways. Today, at least two-thirds of biomanufacturers are facing at least minor constraints at clinical and commercial stages of manufacturing. This is according to data released in our 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. Further, the 302 biotherapeutic developers and contract manufacturing org...